Shengda Biology had 1 block trade on March 23, with a total transaction amount of 7.525 million yuan and a premium rate of -2.02%

MaticHoleFiller · 2026-03-23T22:35:15+00:00

Shengda Biotech's stock price fell 7.97% on March 23, closing at 15.36 yuan. There was one block trade involving 500,000 shares and a transaction value of 7.525 million yuan. Recently, the stock has declined a total of 19.03%, with net outflows of main capital amounting to 24.6691 million yuan. Investors should exercise caution.

MaticHoleFiller

2026-03-23 22:35:15

Abstract generation in progress

Trading stocks relies on Golden Kylin Analysts’ reports—authoritative, professional, timely, comprehensive—helping you uncover potential thematic opportunities!

On March 23, Santar Biotech closed down 7.97%, with a closing price of 15.36 yuan. One block trade occurred, totaling 500,000 shares with a transaction amount of 7.525 million yuan.

The first transaction price was 15.05 yuan, with 500,000 shares traded, totaling 7.525 million yuan, with a premium rate of -2.02%. The buyer’s broker was Wanjia Securities Co., Ltd. Shanghai Pudong New Area Century Avenue Securities Branch, and the seller’s broker was Huafu Securities Co., Ltd. Shaoxing Shangyu Min Avenue Securities Branch.

Further statistics show that in the past three months, this stock has had one block trade, with a total transaction amount of 7.525 million yuan. Over the last five trading days, the stock has fallen a total of 19.03%, with main funds net outflows of 24.6691 million yuan.

Disclaimer: The market carries risks; investments should be cautious. This article is automatically published based on third-party databases and does not represent Sina Finance’s views. Any information appearing herein is for reference only and does not constitute personal investment advice. Please refer to official announcements for accuracy. If you have questions, contact biz@staff.sina.com.cn.

Massive information, precise analysis, all on Sina Finance APP

Editor: Xiao Lang Express

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.